Ebrahim Variava to Reverse Transcriptase Inhibitors
This is a "connection" page, showing publications Ebrahim Variava has written about Reverse Transcriptase Inhibitors.
Connection Strength
0,054
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
Score: 0,054